1

COVID-19: A comparative study of severity of patients hospitalized during the first and the second wave in South Africa.

Authors and affiliations

Caroline Maslo¹, Angeliki Messina², Anchen Laubscher¹, Mande Toubkin³, Liza Sitharam⁴, Charles Feldman⁵, Guy A Richards⁶

¹Netcare Clinical Division, Netcare Limited, Johannesburg, South Africa

²Antibiotic Stewardship Unit, Netcare Limited, Johannesburg, South Africa

³Emergency and Trauma Department, Netcare Limited, Johannesburg, South Africa

⁴ Infection Control, Netcare Coastal Region, Netcare Limited, Johannesburg, South Africa

⁵ Department of Internal Medicine, Faculty of Health Sciences, University of the

Witwatersrand, Johannesburg, South Africa

⁶ Department of Critical Care, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Contact information

Corresponding author

Dr Caroline Maslo, MD, PhD, Netcare Limited, 76 Maude Street, Sandton 2196, Johannesburg, South Africa. Email: <u>caroline.maslo@netcare.co.za</u>

Abstract

Background

South Africa has experienced two waves of COVID-19 infections, the second of which was inter alia attributed to the emergence of a novel SARS-CoV2 variant, 501Y.V2. This variant possibly has increased virulence and may be associated with increased mortality. The objective of this study was to determine if patients admitted in the second wave had more severe illness and higher mortality than those admitted in the first.

Methods

We analysed and compared the characteristics, biological severity markers, treatments, level of care and outcomes of patients hospitalised in a private hospital in the Eastern Cape Province, South Africa.

Results

Compared to the first wave, patients admitted in the second were older and less likely to have co-morbidities. In contrast, the D-dimer and interleukin-6 (IL-6) levels were significantly higher. Despite this, significantly less patients were admitted to ICU and/or were mechanically ventilated. The total length of hospital stay was identical in both groups. Whereas the overall mortality was not significantly higher during the second wave, the ICU mortality was. Those that died in the second wave were older than those in the first wave. Multivariable logistic regression showed that being admitted during the second wave was an independent risk factor for mortality.

Conclusion

This study appears to confirm previous reports that the 501Y.V2 variant is possibly more virulent as indicated by the higher levels of D-dimer and IL-6, the slight increase in mortality of hospitalised patients and the higher ICU mortality in the second wave.

Key words

COVID-19; SARS-CoV2; 501Y.V2 variant; mortality; South Africa

INTRODUCTION

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) which causes COVID-19, has given rise to a global pandemic. Many countries have seen multiple waves of infection, with South Africa having experienced two [1]. South Africa reported its first case on 2 March 2020, with the epidemic curve peaking in the first week of July 2020, followed by a decline until the second week of September [2]. The second wave began as an isolated cluster of cases in October 2020 in the Eastern Cape Province (ECP) of South Africa and then spread rapidly to involve the rest of the country. By October 15th, all samples routinely genotyped in the ECP were positive for 501Y.V2 [3] and the rapidly accelerating incidence of cases in that province, and nationally, was putatively linked to the emergence of a novel SARS-CoV-2 variant, 501Y.V2 or B.1.351.

As new variants emerge, a select few have demonstrated increased transmissibility and possibly clinical severity [4-5]. Until November 2020, there had been a shift towards patients that were younger, with fewer associated comorbidities and lower in-hospital mortality. The latter was probably multifactorial and linked to the younger age, the lower comorbidity burden, possibly better medical management and less severe disease [1, 6-9]. However, the B 1.1.7 variant that emerged in November 2020 in the south of England and spread to both Europe and the United States (US) has been associated with higher transmissibility and mortality [4-5-10]. Recently, Pearson et al., using a model developed in the United Kingdom (UK) found evidence indicating that the 501Y.V2 variant may cause more severe disease [11]. Similarly, the South African National Institute for Communicable Diseases (NICD), by analysing the data from the National Active Surveillance system for COVID-19 hospitalisations, has reported a 20% increased mortality among individuals hospitalised with COVID-19 during the second wave [12].

5

In an attempt to confirm whether the 501Y.V2 variant does confer an increase in severity, we conducted a study to assess characteristics, severity of illness and mortality in patients hospitalised during the second wave and compared this with those hospitalised in the first, in a private hospital in the ECP.

METHODS

Study design

We conducted a retrospective study of hospitalised cases of SARS-CoV-2 infection in Greenacres Hospital (a member of the Netcare group of Hospitals) in the ECP, South Africa. The first COVID-19 patient was admitted on 28 March 2020, and thereafter the number of admissions increased to peak in the week of 14 June 2020 (week 14) and decreased until 22 August 2020. The second wave started on 25 October 2020 to peak on 8 November 2020 (week 34) and decreased from 6 December 2020 to 24 January 2021. We extracted data from two equal six-week periods in each of the waves, during both of which there were continuous admission rates of more than 40 patients per week (Fig 1). We categorized patients into the first wave for admissions between 14 June and 25 July 2020 (weeks 13 to 18) and the second wave for admissions between 8 November to 19 December 2020 (weeks 34 to 39). The criteria for enrolment in the study were hospitalisation and a positive reverse transcriptase polymerase chain reaction (RT-PCR) obtained from a nasopharyngeal swab in consecutive hospitalised patients. Patients not admitted for COVID-19 and those that died on admission were excluded from the study.

This study was approved by Pharma-ethics as complying with the Ethical Standards of Clinical Research based on current U.S. Food and Drug Administration (FDA), International Conference for Harmonization (ICH), Good Clinical Practice (GCP), Declaration of Helsinki and current local Ethics guidelines (reference 200923584).

6

Data collected

Patient characteristics, therapy, highest level of care required, need for mechanical ventilation, length of stay and mortality were extracted from the Netcare electronic billing system (SAP ISH- SAP ERP ENHANCE package, version 6.07). Laboratory data were collected from the Bluebird Health platform (Intelligent Medical Systems, South Africa).

Statistical analysis

Data is provided as numbers and percentages. Continuous variables are presented as medians and interquartile range (IQR) or means and standard deviations, as appropriate. Statistical comparisons between the two groups were made using the Mann-Whitney U test or the Student's t test for continuous variables, with the use of the Fisher's exact test for categorical variables. Analysis of factors potentially associated with mortality was performed using multivariate logistic regression. Statistical significance was set at p< 0.05. All statistical analyses were conducted using IBM SPSS version 27.0.1.0.

RESULTS

Overall, 550 patients were admitted during the first wave and 685 patients during the second. The distribution of COVID-19 hospital admissions is shown in figure 1. During the designated study periods, 303 patients with COVID-19 were admitted during the first wave and 357 patients during the second.

The patients' epidemiological characteristics are shown in table 1. Those admitted during the second wave were significantly older (median 57 vs 54 years; p=0.03) and there were more patients without any comorbidities (47% vs 36.9%; p=0.008). In addition, less patients had hypertension (32.2% vs 45.2%; p<0.001) but there was no difference in the prevalence of diabetes mellitus, chronic cardiorespiratory or cerebrovascular diseases, or HIV positivity.

7

The laboratory data on admission indicated that the D-dimer and interleukin-6 (IL-6) levels were higher in patients admitted during the second wave (1.1 vs 0.9 mg/l, p=0.005 and 55.1 vs 32.4 pg/ml, p < 0.001, respectively) while no difference was observed in the C-reactive protein (CRP) levels, or the neutrophil to lymphocyte ratio (NLR) (Table 2).

Table 3 summarises medications and supportive treatment. Over 90% of patients in both waves received glucocorticoid and anticoagulant therapy. Remdesivir was not available in South Africa during the first wave study period, but was prescribed in 37.2% of patients in the second. There was also an increase in prescription of tocilizumab in the second wave as compared to the first (49.5% vs 20.8%, p=0.03). Less patients were admitted to the intensive care unit (ICU) in the second wave versus the first (35% vs 48.5%; p=0.03) and fewer patients received mechanical ventilation during the second wave as compared to the first (8.9% vs 15.5%, p=0.009).

As shown in table 4, the number of days between hospital and ICU admission was also longer in the second wave (3.13 days vs 1.55 days, p=0.01) and fewer patients were admitted to the ICU within 24 hours of hospital admission. There was no difference in hospital and the ICU length of stay between the two waves. Overall mortality was 32.6% in the first wave and 36.4% in the second. However, ICU mortality was significantly higher in the second compared with the first (74.4% vs 57.1%, p=0.002).

Multivariate analysis of factors associated with mortality identified age, ICU admission, mechanical ventilation, treatment with tocilizumab and admission during the second wave as independently associated with death (Table 5).

8

DISCUSSION

In contrast with most reports of second waves outside of South Africa, our study found that patients hospitalised during the second wave in a single hospital in the ECP were significantly older than in the first [6-8]. Of note, the second wave coincided with the end of the school and university years and also the annual summer public holidays in which there was significant liberalisation of lockdown rules. As such, spread among younger people would have been expected to be greater.

Patients hospitalised during the second wave had fewer co-morbidities, which was noted in some studies but was usually associated with younger age of the patients. One plausible explanation would be related to behavioural change in those with chronic conditions as they became more aware of an increased risk for adverse outcomes.

In the current study, laboratory parameters indicating increased risk of severe COVID-19 such as N/L ratio and CRP were identical in both groups, but D-dimer and IL-6 levels were higher on admission in the second wave. It has previously been suggested by Wungu et al., in a meta-analysis comparing cardiac markers as predictive factors in COVID-19 infection that the D-dimer level was the best predictor of severity and mortality [13]. IL-6 levels were also shown to be significantly elevated in patients with severe disease relative to those with less severe disease. In a recent study from Sabaka et al., among patients with COVID-19 in a long-term care facility, IL-6 was the most robust predictor of hypoxemia when compared to other laboratory parameters such as the CRP and D-dimer levels [14]. The higher levels of IL-6 and D-dimer levels in the current study do, therefore, suggest that those admitted in the second period had higher disease acuity on admission.

In contrast, the proportion of patients admitted to the ICU and the proportion that received mechanical ventilation were lower in the second wave. ICU admissions within the first 24

9

hours of following hospital admission were also lower in the second wave. The latter has been a worldwide phenomenon, and is related to the fact that it is currently recognised that respiratory failure could be effectively treated with high flow nasal oxygen treatment without the necessity for early intubation [15]. While lack of capacity in the ICU setting may have contributed to the higher mortality, the lower absolute number of patients admitted to the ICU in the second wave suggest that shortage of ICU beds was not an issue in the current study.

Prescription of corticosteroids and anticoagulants were similar in both groups. Remdesivir was not available during the first study period but was prescribed to more than a third of patients during the second. A greater proportion of patients in the second wave also received tocilizumab as doctors became more familiar with its use and possibly also because patients in the second wave had higher IL-6 levels. Both remdesivir and tocilizumab were initially reported to be effective in shortening length of stay and preventing death [16, 17]; however, this remains controversial [18, 19].

Whereas it could be assumed that the knowledge and experience gained from managing patients in the first wave would have impacted positively on the outcomes in the second wave, we observed a significant increase in mortality and shorter time to death (albeit not significant) in those admitted to ICU during this period.

Other studies have reported a similar lack of improvement in mortality in patients admitted to ICU between the first and the second waves despite apparently better management. Karagiannidis *et al.*, reported a 50% drop in ICU admissions during the second wave of the pandemic in Germany but in contrast the prognosis of ICU patients, remained unchanged, with the mortality greater than 50% [20]. Contou *et al.*, reported their experience of ICU admissions during the second wave in France and did not observe any decrease in ICU

10

mortality which remained at 50% [21]. Of note, none of those patients received remdesivir or tocilizumab.

It is probable that patients that were transferred to ICU were more severe in the second wave than in the first, as both the IL-6 and D-dimer levels were elevated to a greater extent than in the first, and also because patients were managed for longer in the general wards on noninvasive respiratory support prior to ICU admission. This potentially could mean that those that failed to respond to these oxygen delivery devices were those with progressive disease who consequently had a worse prognosis.

Finally, the multivariate regression analysis identified admission during the second wave as an independent factor associated with death. Patients in the second wave were each assumed to be infected with the 501Y.V2 lineage of SARS-CoV2 as, since as mentioned above, all samples that had been routinely genotyped in the Eastern Cape Province were positive for 501Y.V2 from October 2020 [3]. For all these reasons, the current study potentially confirms the increased severity of this variant as had been previously reported in the National Surveillance study [12].

There are limitations in our study. This was a single centre study and thus the results cannot be generalised to other regions in South Africa, nor to other countries. Patient numbers were, however, adequate. Furthermore, being a single centre study, it also excluded our need to have to evaluate the impact that different skill sets and resource availability at different hospitals may have had on the outcomes. We could not perform genotyping for all patients included in the study and thus relied on screening results performed by the Kwazulu-Natal Research Innovation and Sequencing Platform (KRISP), which indicated that all the patients genotyped in the second wave in the ECP had the variant. As most data were extracted from our billing platform, certain clinical data were missing. Obesity, which is known to be an

11

important risk factor for COVID-19 severity, was not evaluated as the body mass indices were not recorded [22]. Data on alternative non-invasive oxygen strategies, such as high frequency nasal oxygen delivery devices were also not available. Patients in the second wave did have higher IL-6 and D-dimer levels on admission but the date of symptom onset was not recorded and although admission delays could not be excluded, all patients presenting via the emergency department were admitted promptly.

CONCLUSION

This study indicates that the IL-6 and D-dimer levels were higher in patients during the second wave compared with the first, the ICU mortality was significantly higher, and the multivariate analysis showed that admission within the second wave was independently associated with mortality. As such it is possible that 501Y.V2 variant is more virulent than the original variant although confounders are present.

REFERENCES

- 1- Fan G, Yang Z, Lin Q, Zhao S, Yang L, He D. Decreased Case Fatality Rate of COVID
 19 in the Second Wave: A study in 53 countries or regions. Transbound Emerg Dis 2020
 Sep 6. doi: 10.1111/tbed.13819. Epub ahead of print. PMID: 32892500.
- 2- An update on COVID-19 outbreak in South Africa. The first and the second wave of COVID-19 cases in South Africa, January 2021. January 2021, Vol. 20 (1). Available at: <u>https://www.nicd.ac.za/wp-content/uploads/2021/01/An-update-on-COVID-19-outbreakin-South-Africa_The-first-and-second-wave.pdf</u>. Accessed 6 April 2021.
- 3- Tegally H, Wilkinson E, Giovanetti M, *et al.* Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Available at: https://www.medrviy.org/content/10.1101/2020.12.21.20248640v1. Accessed 16 April

https://www.medrxiv.org/content/10.1101/2020.12.21.20248640v1. Accessed 16 April 2021.

- 4- Davies NG, Abbott S, Barnard RC, *et al.* Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. Available at: https://www.medrxiv.org/content/10.1101/2020.12.24.20248822v2. Accessed 30 March 2021.
- 5- Iacobucci G. Covid-19: New UK variant may be linked to increased death rate, early data indicate. BMJ 2021;372:n230.
- 6- Saito S, Asai Y, Matsunaga N, *et al.* First and second COVID-19 waves in Japan: A comparison of disease severity and characteristics. J Infect 2021;4:84-123
- 7- Mollinedo-Gajate I, Villar-Álvarez F, Zambrano-Chacón MLÁ. *et al.* First and Second Waves of Coronavirus Disease 2019 in Madrid, Spain: Clinical Characteristics and Hematological Risk Factors Associated With Critical/Fatal Illness. Crit Care Explor 2021;3(2):e0346.

- 8- Vahidy FS, Drews AL, Masud FN, *et al.* Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. JAMA 2020;324(10):998-1000.
- 9- Jalali SF, Ghassemzadeh M, Mouodi S, *et al.* Epidemiologic comparison of the first and second waves of coronavirus disease in Babol, North of Iran. Caspian J Intern Med 2020;11(Suppl 1):544-550.
- 10- Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ 2021 Mar 9;372:n579.
- 11- Pearson CAB, Russell TW, Davies N, Kucharski AJ. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. Available at: <u>https://cmmid.github.io/topics/covid19/reports/sanovel-</u> variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf. Accessed

variant/2021_01_11_fransmissibility_and_severity_of_501Y_V2_in_SA.pdf. Accessed 16 April 2021.

- 12- Jassat W, Mudara C, Ozougwu L, *et al.* Increased mortality among individuals hospitalised with COVID-19 during the second wave in South Africa. Available at: https://www.medrxiv.org/content/10.1101/2021.03.09.21253184v1, Accessed 9 April 2021.
- Wungu CDK, Khaerunnisa S, Putri EAC, *et al.* Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19. Int J Infect Dis 2021;105:551-559.
- 14- Sabaka P, Koščálová A, Straka I, *et al.* Role of interleukin 6 as a predictive factor for a severe course of Covid-19: retrospective data analysis of patients from a long-term care facility during Covid-19 outbreak. BMC Infect Dis 2021;21(1):308. Available at: https://doi.org/10.1186/s12879-021-05945-8. Accessed 9 April 2021.

14

- 15- Mellado-Artigas R, Ferreyro BL, Angriman F, *et al*. High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure. Crit Care **2021** ;25(1):58.
- 16- Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the Treatment of Covid-19 -Final Report. N Engl J Med **2020**; 383(19):1813-1826.
- 17- Lundh A. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med
 2021 Mar 3:10.1056/NEJMc2100217#sa1. doi: 10.1056/NEJMc2100217. [Epub ahead of print]. PMID: 33657286.
- 18- Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should remdesivir be used for the treatment of patients with COVID-19? Rapid, living practice points from the American College of Physicians (Version 2). Ann Intern Med 2021: M20-8101 [Epub ahead of print].
- 19- Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ 2021; 372:n84.
- 20- Karagiannidis C, Windisch W, McAuley DF, Welte T, Busse R. Major differences in ICU admissions during the first and second COVID-19 wave in Germany. Lancet Respir Med 2021: S2213-2600(21)00101-6. doi: 10.1016/S2213-2600(21)00101-6. Epub ahead of print. PMID: 33684356.
- 21-Contou, D, Fraissé, M, Pajot, O, Tirolien JA, Mentec H, Plantefeve. Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave? Crit Care 2021; 25, 3
- 22- Popkin BM, Du S, Green WD, *et al.* Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev. 2020; 21(11):e13128.

Figure legend

Figure 1. Weekly distribution of COVID-19 admissions during the first and second waves in the ECP, South Africa.

Tables legends

Table 1. Comparison of characteristics of patients admitted with COVID-19 in the first and second waves in the ECP, South Africa.

Table 2. Comparison of severity markers levels at admission of patients between the first and second waves.

 Table 3. Comparison of treatment administered in the first and second waves in the ECP,

 South A frice

South Africa

Table 4. Main outcomes of patients hospitalized during the first and second waves in the

 ECP, South Africa

Table 5. Multiple regression model investigating risk factors for death in the ECP, South

 Africa

16

Table 1. Comparison of characteristics of patients admitted with COVID-19 in the first and second waves in the ECP, South Africa.

	First wave	Second wave	ות
	(No=303)	(No=357)	P value
Patients characteristics			
Sex (Male), No (%)	166 (54.7%)	179 (50.1%)	0.23
Age (y), median (IQR)	54 (15.4)	57 (20)	0.03
Age at death (y), median (IQR)	60 (15)	65 (20)	0.008
Age categories	No (%)	No (%)	
0-29 years	8(3%)	14 (4%)	0.488
30-59 years	193 (64%)	182 (51%)	< 0.001
≥60 years	102 (34%)	161 (45%)	0.004
Main co-morbidities	No (%)	No (%)	
Diabetes mellitus	82 (27.0%)	99 (27.7%)	0.84
Hypertension	137 (45.2%)	115 (32.2%)	0.0006
Chronic respiratory disease	9 (3%)	16 (4.5%)	0.31
HIV infection	6 (2%)	4 (1.1%)	0.34
Cardiovascular disease	60 (16.5%)	78 (21.8%)	0.08
Cerebrovascular disease	1 (0.3%)	5 (1.4%)	0.13
No co-morbidities	112 (36.9%)	168 (47.0%)	0.008

No., number; IQR, interquartile range; HIV, human immunodeficiency virus

17

Table 2. Comparison of severity markers levels at admission of patients between the first and

second waves.

	Normal	First wave	Second wave		
	range	Median (IQR)	Median (IQR)	P value	
D-dimers (mg/L)	0-0.5	0.9 (1.01)	1.1 (1.46)	0.005	
N/L ratio	1-3	5 (6)	6 (6)	0.27	
C-reactive protein	0.10	124 (1.15)	125 (1.005)	0.61	
(mg/L)	0-10	134 (1.15)	135 (1.005)	0.61	
Interleukin-6 (pg/ml)	< 6.4	32.4 (64.5)	55.1 (96.2)	< 0.001	
Hs-Troponin (ng/L)	0-70	14.7 [21.6]	13.8 [37.5]	0.99	

N/L ratio: Neutrophil-to Lymphocytes ratio

18

Table 3. Comparison of treatment administered in the first and second waves in the ECP,

South Africa

	No. (%)		
	First wave (n=303)	Second wave (n=357)	<i>p</i> -value
Glucocorticoids	273 (90.0%)	323 (90.4%)	0.86
Thromboprophylaxis	276 (91.0%)	331 (92.7%)	0.42
Remdesivir	Not available	133 (37.2%)	N.A
Tocilizumab	63 (20.8%)	177 (49.5%)	< 0.001
Number of ICU admissions	147 (48.5%)	125 (35%)	< 0.001
Invasive mechanical ventilation	47 (15.5%)	32 (8.9%)	0.009

N.A not applicable; No.: number

Table 4. Main outcomes of patients hospitalized during the first and second waves in the

ECP, South Africa

	Mean \pm SD		
	First wave (n=303)	e (n=303) Second wave (n=357)	
Days between hospital admission and death	11.74 <u>+</u> 7.63	11.14 <u>+</u> 9.26	0.6
Days between ICU admission and death	10.67 ± 7.58	10.32 <u>+</u> 8.84	0.72
Length of ICU stay, days	11.24 <u>+</u> 11.16	9.20 <u>+</u> 9.11	0.1
Length of hospital stay, days	10.49 <u>+</u> 9.8	10.20 ± 8.01	0.67
Days between hospital and ICU admission	1.55 <u>+</u> 2.32	3.13 <u>+</u> 5.46	0.001
	No.(%)		
Outcomes	First wave (n=303)	Second wave (n=357)	<i>p</i> -value
Admission to ICU \leq 24 hours	97/147 (65.9%)	63/125 (50.4%)	0.01
Secondary infections	5 (1.6%)	5 (1.4%)	0.83
Intensive care unit mortality	84/147 (57.1%)	93/125 (74.4%)	0.002
Overall mortality	98/303 (32.3%)	130/357 (36.4%)	0.26

SD: Standard deviation; No.: number

Table 5. Multiple regression model investigating risk factors for death in the ECP, South

Africa

В	SE	Exp(B)	<i>p</i> -value
0.910	0.631	1.095	< 0.001
-0.129	0.231	0.879	0.577
0.410	0.237	1.507	0.083
-2.804	0.292	0.061	< 0.001
2.011	0.398	7.47	< 0.001
-0.563	0.318	0.57	0.07
0.677	0.256	1.968	0.008
0.789	0.287	2.202	0.006
	0.910 -0.129 0.410 -2.804 2.011 -0.563 0.677	0.910 0.631 -0.129 0.231 0.410 0.237 -2.804 0.292 2.011 0.398 -0.563 0.318 0.677 0.256	0.910 0.631 1.095 -0.129 0.231 0.879 0.410 0.237 1.507 -2.804 0.292 0.061 2.011 0.398 7.47 -0.563 0.318 0.57 0.677 0.256 1.968

B: Non-standardized βcoefficient. SE: Standard error of B.

21

Figure 1. Weekly distribution of COVID-19 admissions during the first and second waves in





Notes

Author's contribution

CM: conception, methodology, formal analysis, writing original draft, writing-review and editing. AL: supervision, resources and writing-review. MT and LS: data acquisition. AM: medication data and writing-review. CF and GR: review and interpretation of results, writing-review and editing. All authors read, critically reviewed and approved the final version.

Acknowledgments

The authors warmly acknowledge Dr M. Butae, Dr J. Dryer, Dr N. Hendricks, Dr. L Kruger,

Dr M. Jansen, Dr Y. Jansen, Dr H.Maepa, Dr S. Meel, Dr P. Meel, Dr P. Musoke, Dr D.

Porter, Dr H. Potgieter and all the staff of Greenacres Hospital who have tirelessly provided care for COVID-19 patients during this pandemic.

Funding statement

There was no funding source for this study

Competing interest Statement

The authors have declared no competing interest.

Availability of data and materials

The dataset used and analysed for the current study is available from the corresponding author on reasonable request.

Ethics approval

This study was approved by Pharma-ethics as complying with the Ethics Standard of Clinical research based on current FDA, ICH, GCP, Declaration of Helsinki and current local Ethics under the number 200923584.